Neurogene

NGNEPhase 1

New York, United StatesFounded 2024neurogene.com

Neurogene is a public, clinical-stage biotech (Nasdaq: NGNE) founded in 2018 with a mission to turn devastating neurological diseases into treatable conditions. The company's core innovation is the EXACT technology, a microRNA-based platform for controlled transgene expression, which underpins its lead candidate NGN-401 for Rett syndrome, currently in a registrational Phase 1/2 trial. With a seasoned leadership team combining deep scientific, clinical, and financial expertise, Neurogene is advancing a pipeline focused on high-unmet-need rare neurological disorders.

Market Cap

$295.1M

Founded

2024

Focus

RNA & Gene Therapy

AI Company Overview

Technology Platform

EXACT™ technology: a proprietary microRNA-based transgene regulation platform designed to provide controlled, cell-specific gene expression to enhance the safety and therapeutic window of gene therapies for complex neurological disorders.

Pipeline Snapshot

1 drug in pipeline

Drug	Indication	Stage
NL-201 + Pembrolizumab Injection [Keytruda]	Solid Tumor	Phase 1

Funding History

Total raised: $308M

IPO$125MUndisclosedNov 9, 2023

Series B$115MEcoR1 CapitalSep 15, 2021

Series A$68MEcoR1 CapitalJan 15, 2018

Opportunities

The primary opportunity is the successful development and approval of NGN-401 for Rett syndrome, a severe disorder with no disease-modifying treatments.

Furthermore, the validated EXACT platform technology can be leveraged to develop new gene therapies for other rare neurological disorders where controlled gene expression is critical, creating a pipeline expansion opportunity.

Risk Factors

Key risks include clinical trial failure or safety issues with lead candidate NGN-401, regulatory hurdles despite Breakthrough Designation, the need for future dilutive financing, competition from other therapeutic modalities, and the challenges of scaling manufacturing and commercializing a high-cost, one-time therapy.

Competitive Landscape

Neurogene competes with other gene therapy developers in Rett syndrome (e.g., Taysha Gene Therapies) and broader regulated gene therapy platforms. Its main differentiation is the EXACT technology, designed specifically to prevent overexpression toxicity associated with MECP2, potentially offering a superior safety profile crucial for central nervous system disorders.